Puma Biotechnology Inc (PBYI) Financial Statements (2025 and earlier)

Company Profile

Business Address 10880 WILSHIRE BLVD.
LOS ANGELES, CA 90024
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:86,83848,91646,54669,84993,389111,644
Cash and cash equivalent69,21984,58576,20163,13185,29360,037
Short-term investments31,74611,3544,87318,9758,09651,607
Other undisclosed cash, cash equivalents, and short-term investments(14,127)(47,023)(34,528)(12,257)  
Restricted cash and investments    8,8508,8508,850
Receivables32,01147,83740,35032,52625,54328,896
Inventory, net of allowances, customer advances and progress billings8,7247,0804,5267,1093,4543,170
Inventory8,7247,0804,5267,1093,4543,170
Prepaid expense5,8674,4175,9028,98411,26213,259
Deferred rent asset     198154
Other current assets919122,4294473,443323
Other undisclosed current assets14,12747,02334,52812,257  
Total current assets:147,658156,185134,281140,022146,139166,296
Noncurrent Assets
Operating lease, right-of-use asset4,5797,79211,36214,01716,40418,522
Property, plant and equipment5158551,1461,7562,4813,304
Intangible assets, net (including goodwill)51,13160,87170,61066,12574,14040,461
Intangible assets, net (excluding goodwill)51,13160,87170,61066,12574,14040,461
Prepaid expense1192,5242,069611  
Restricted cash and investments2,0912,0912,5913,3113,3114,323
Deferred income tax assets7,075     
Other undisclosed noncurrent assets165210 7431,7451,999
Total noncurrent assets:65,67574,34387,77886,56398,08168,609
TOTAL ASSETS:213,333230,528222,059226,585244,220234,905
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities42,40759,61059,474103,74973,40188,213
Accounts payable5,5096,8896,44011,17412,07619,183
Accrued liabilities36,89852,72153,03492,57561,32569,030
Debt45,32933,997  14,2862,624
Other liabilities      
Other undisclosed current liabilities8,3755,77518,0105,83726,568 
Total current liabilities:96,11199,38277,484109,586114,25590,837
Noncurrent Liabilities
Long-term debt and lease obligation21,71965,65998,307113,067103,57422,643
Long-term debt, excluding current maturities21,71965,65998,30797,09284,025 
Liabilities, other than long-term debt 1,7367,15511,87137233 
Accounts payable and accrued liabilities 1211213737233 
Other liabilities 121     
Operating lease, liability 1,4947,03411,83415,97519,54922,643
Other undisclosed noncurrent liabilities1,6424,89012,7896,34132,109103,962
Total noncurrent liabilities:25,09777,704122,967119,445135,916126,605
Total liabilities:121,208177,086200,451229,031250,171217,442
Equity
Equity, attributable to parent92,12553,44221,608(2,446)(5,951)17,463
Common stock555444
Additional paid in capital1,407,0001,398,6051,388,3581,364,3091,331,6761,295,033
Accumulated other comprehensive income (loss)6(4) (2) 62
Accumulated deficit(1,314,886)(1,345,164)(1,366,755)(1,366,757)(1,337,631)(1,277,636)
Total equity:92,12553,44221,608(2,446)(5,951)17,463
TOTAL LIABILITIES AND EQUITY:213,333230,528222,059226,585244,220234,905

Income Statement (P&L) ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues230,468235,637228,031253,155225,110272,260
Cost of revenue
(Cost of Product and Service Sold)
(64,404)(62,682)(55,093)(63,701)  
Gross profit:166,064172,955172,938189,454225,110272,260
Operating expenses(135,098)(140,315)(149,218)(188,164)(255,512)(311,358)
Operating income (loss):30,96632,64023,7201,290(30,402)(39,098)
Nonoperating income (expense)(6,866)(9,966)785(30,092)(29,386)(36,497)
Investment income, nonoperating4,7242,6058131604892,847
Other nonoperating income (expense)862759(28)292367128
Interest and debt expense(12,452)(13,330)(11,592)(8,146)(14,046)(8,047)
Income (loss) from continuing operations before equity method investments, income taxes:11,6489,34412,913(36,948)(73,834)(83,642)
Other undisclosed income (loss) from continuing operations before income taxes12,45213,330(12,456)8,14614,046 
Income (loss) from continuing operations before income taxes:24,10022,674457(28,802)(59,788)(83,642)
Income tax expense (benefit)6,178(1,083)(455)(324)(207)(53)
Income (loss) from continuing operations:30,27821,5912(29,126)(59,995)(83,695)
Loss before gain (loss) on sale of properties:(29,126)(59,995)(83,695)
Other undisclosed net income      8,100
Net income (loss) available to common stockholders, diluted:30,27821,5912(29,126)(59,995)(75,595)

Comprehensive Income ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):30,27821,5912(29,126)(59,995)(75,595)
Comprehensive income (loss):30,27821,5912(29,126)(59,995)(75,595)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent10(4)2(2)(62)74
Comprehensive income (loss), net of tax, attributable to parent:30,28821,5874(29,128)(60,057)(75,521)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: